STRATA Skin Sciences to Participate in the Benchmark 12th Annual Discovery One-on-One Investor Conference
01 Diciembre 2023 - 7:00AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology
company dedicated to developing, commercializing and marketing
innovative products for the treatment of dermatologic conditions,
today announced that the company will be participating in the
Benchmark 12th Annual Discovery One-on-One Investor Conference
being held in New York City on December 7, 2023. Details for the
event are as follows:
Benchmark’s 12th Annual Discovery One-on-One Investor
ConferenceDate: December 7,
2023Location: New York Athletic Club, New York,
NY
For more information about the conference, please visit the
website, or to schedule one-on-one meetings with management, please
email sskn@cg.capital.About STRATA Skin Sciences,
Inc.STRATA Skin Sciences is a medical technology company
dedicated to developing, commercializing and marketing innovative
products for the in-office treatment of various dermatologic
conditions such as psoriasis, vitiligo, and acne. Its products
include the XTRAC® excimer laser, VTRAC® lamp systems, and the
TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S.
through its unique Partnership Program. STRATA’s popular
partnership approach includes a fee per treatment cost structure
versus an equipment purchase, installation and use of the device,
on-site training for practice personnel, service and maintenance of
the equipment, dedicated account and customer service associates,
and co-op advertising support to help raise awareness and promote
the program within the practice.
Safe HarborThis press release
includes "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives,
expectations and intentions and may contain words such as “will,”
“may,” “seeks,” and “expects,” that suggest future events or
trends. These statements, the Company’s ability to launch and sell
an acne treatment device and to integrate that device into its
product offerings, the Company’s ability to develop, launch and
sell products recently acquired or to be developed in the future,
the Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and
www.strataskinsciences.com.
Investor Contact:Rich
CockrellCG CapitalPhone: +1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024